Cartesian Therapeutics announces landmark study in The Lancet Neurology of first successful clinical trial of RNA cell therapy in autoimmunity
Cartesian Therapeutics has successfully treated patients with generalized myasthenia gravis using an RNA CAR-T therapy. The trial demonstrated marked and long-lasting clinical improvement, with three patients achieving complete or near-complete eradication of disease symptoms.
SourceCartesian Therapeutics·JournalThe Lancet Neurology·TypeRandomized controlled/clinical trial·DateJun 22, 2023